Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

FDA starts speedy review of Merck/Pfizer's PD-L1 inhibitor

FDA starts speedy review of Merck/Pfizer's PD-L1 inhibitor The company has been buying in assets to flesh out its oncology portfolio, and in addition to avelumab also acquired Medivation for $14bn to add prostate cancer treatment Xtandi (enzalutamide) and

Astellas buys Ganymed to boost immuno-oncology pipeline

Astellas buys Ganymed to boost immuno-oncology pipeline Astellas has been working hard to build up its oncology portfolio, currently headed by prostate cancer treatment Xtandi (enzalutamide), which is partnered with Pfizer. ... The acquisition of Ganymed will enable Astellas to further expand our oncology

Pfizer decides against long-discussed break-up

Pfizer decides against long-discussed break-up Medivation adds another fast-growing prostate cancer treatment Xtandi (enzalutamide), which posted $1.9bn in sales last year.

Deal Watch August 2016

Deal Watch August 2016 35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

Pfizer rides out Sanofi and confirms $14bn Medivation takeover

Pfizer rides out Sanofi and confirms $14bn Medivation takeover Success of cancer specialist’s drug Xtandi followed by work on other cancer drugs.  . ... There is plenty of room for further growth of Xtandi, according to analysts.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics